Terms: = Breast cancer AND CDK6, MGC59692, 1021, Q00534, ENSG00000105810, PLSTIRE AND Treatment
187 results:
1. Withaferin A alters the expression of microRNAs 146a-5p and 34a-5p and associated hub genes in MDA-MB-231 cells.
Shuaib M; Chaudhri S; Kumar S
Biomol Concepts; 2024 Jan; 15(1):. PubMed ID: 38525814
[TBL] [Abstract] [Full Text] [Related]
2. CD63
Sun J; Du R; Li X; Liu C; Wang D; He X; Li G; Zhang K; Wang S; Hao Q; Zhang Y; Li M; Gao Y; Zhang C
Cancer Lett; 2024 Apr; 588():216747. PubMed ID: 38403110
[TBL] [Abstract] [Full Text] [Related]
3. PMM2 controls ERα levels and cell proliferation in ESR1 Y537S variant expressing breast cancer cells.
Cipolletti M; Acconcia F
Mol Cell Endocrinol; 2024 Apr; 584():112160. PubMed ID: 38266771
[TBL] [Abstract] [Full Text] [Related]
4. A new treatment for breast cancer using a combination of two drugs: AZD9496 and palbociclib.
Nave O; Shor Y; Bar R; Segal EE; Sigron M
Sci Rep; 2024 Jan; 14(1):1307. PubMed ID: 38225243
[TBL] [Abstract] [Full Text] [Related]
5. IGF2BP2 Drives Cell Cycle Progression in Triple-Negative breast cancer by Recruiting EIF4A1 to Promote the m6A-Modified cdk6 Translation Initiation Process.
Xia T; Dai XY; Sang MY; Zhang X; Xu F; Wu J; Shi L; Wei JF; Ding Q
Adv Sci (Weinh); 2024 Jan; 11(1):e2305142. PubMed ID: 37983610
[TBL] [Abstract] [Full Text] [Related]
6. Repurposing of approved drugs for targeting CDK4/6 and aromatase protein using molecular docking and molecular dynamics studies.
Yousif FA; Alzain AA; Alraih AM; Ibraheem W
PLoS One; 2023; 18(9):e0291256. PubMed ID: 37682937
[TBL] [Abstract] [Full Text] [Related]
7. Discovery of dual PARP and cdk6 inhibitors for triple-negative breast cancer with wild-type BRCA.
Wang C; Luo H; Chen X; Zhang Y; Lu D; Liu X; Yin F; Li S; Kong L; Wang X
Bioorg Chem; 2023 Oct; 139():106683. PubMed ID: 37379778
[TBL] [Abstract] [Full Text] [Related]
8. Ethyl acetate extract of Antenoron Filiforme inhibits the proliferation of triple negative breast cancer cells via suppressing Skp2/p21 signaling axis.
Liao Y; Li S; An J; Yu X; Tan X; Gui Y; Wang Y; Huang L; Zhou S; Wang D
Phytomedicine; 2023 Jul; 116():154856. PubMed ID: 37187035
[TBL] [Abstract] [Full Text] [Related]
9. A functional genetic screen for metabolic proteins unveils GART and the
Cipolletti M; Leone S; Bartoloni S; Acconcia F
Front Endocrinol (Lausanne); 2023; 14():1129162. PubMed ID: 37143728
[TBL] [Abstract] [Full Text] [Related]
10. cdk6 is activated by the atypical cyclin I to promote E2F-mediated gene expression and cancer cell proliferation.
Quandt E; Masip N; Hernández-Ortega S; Sánchez-Botet A; Gasa L; Fernández-Elorduy A; Plutta S; Martínez-Láinez JM; Bru S; Munoz-Torres PM; Floor M; Villà-Freixa J; Morris MC; Vidal A; Villanueva A; Clotet J; Ribeiro MPC
Mol Oncol; 2023 Jul; 17(7):1228-1245. PubMed ID: 37081792
[TBL] [Abstract] [Full Text] [Related]
11. Wnt Signaling Pathway Collapse upon β-Catenin Destruction by a Novel Antimicrobial Peptide SKACP003: Unveiling the Molecular Mechanism and Genetic Activities Using breast cancer Cell Lines.
Selvarathinam K; Subramani P; Thekkumalai M; Vilwanathan R; Selvarajan R; Abia ALK
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770598
[TBL] [Abstract] [Full Text] [Related]
12. A novel ribociclib derivative WXJ-103 exerts anti-breast cancer effect through CDK4/6.
Ji J; Zhang Z; He X; Pan G; Li G; Lv J; Xu Y; Xie M; Feng J; Wang W; Liu B; Ma J; Wang X
Anticancer Drugs; 2023 Aug; 34(7):803-815. PubMed ID: 36729405
[TBL] [Abstract] [Full Text] [Related]
13. Neoadjuvant endocrine therapy with or without palbociclib in low-risk patients: a phase III randomized double-blind SAFIA trial.
Alsaleh K; Al Zahwahry H; Bounedjar A; Oukkal M; Saadeddine A; Mahfouf H; Bouzid K; Bensalem A; Filali T; Abdel-Razeq H; Larbaoui B; Kandil A; Abulkhair O; Al Foheidi M; Ghosn M; Rasool H; Boussen H; Mezlini A; Haddaoui A; Ayari J; Al Ghamdi M; Errihani H; Abdel-Aziz N; Arafah M; Dabouz F; Bahadoor M; Kullab S; Nabholtz JM;
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6171-6179. PubMed ID: 36680581
[TBL] [Abstract] [Full Text] [Related]
14. Enzymatic Digestion of Cell-surface Heparan Sulfate Alters the Radiation Response in Triple-negative breast cancer Cells.
Krautschneider SL; Troschel FM; Vadillo E; Eich HT; Götte M; Espinoza-Sánchez NA; Greve B
Arch Med Res; 2022 Dec; 53(8):826-839. PubMed ID: 36411172
[TBL] [Abstract] [Full Text] [Related]
15. Obesity and metabolic syndrome are associated with short-term endocrine therapy resistance in early ER + breast cancer.
Bergman R; Berko YA; Sanchez V; Sanders ME; Gonzalez-Ericsson PI; Arteaga CL; Rexer BN
Breast Cancer Res Treat; 2023 Jan; 197(2):307-317. PubMed ID: 36396775
[TBL] [Abstract] [Full Text] [Related]
16. A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial cancer.
Konstantinopoulos PA; Lee EK; Xiong N; Krasner C; Campos S; Kolin DL; Liu JF; Horowitz N; Wright AA; Bouberhan S; Penson RT; Yeku O; Bowes B; Needham H; Hayes M; Sawyer H; Polak M; Shea M; Cheng SC; Castro C; Matulonis UA
J Clin Oncol; 2023 Jan; 41(3):599-608. PubMed ID: 36174113
[TBL] [Abstract] [Full Text] [Related]
17. Gene Expression Profiling between Patient Groups with High and Low Ki67 Levels after Short-term Preoperative Aromatase Inhibitor treatment for breast cancer.
Kajiwara Y; Iwamoto T; Zhu Y; Kochi M; Shien T; Taira N; Doihara H; Toyooka S
Acta Med Okayama; 2022 Aug; 76(4):399-408. PubMed ID: 36123154
[TBL] [Abstract] [Full Text] [Related]
18. Shallow WGS of individual CTCs identifies actionable targets for informing treatment decisions in metastatic breast cancer.
Fernandez-Garcia D; Nteliopoulos G; Hastings RK; Rushton A; Page K; Allsopp RC; Ambasager B; Gleason K; Guttery DS; Ali S; Charles Coombes R; Shaw JA
Br J Cancer; 2022 Nov; 127(10):1858-1864. PubMed ID: 36088510
[TBL] [Abstract] [Full Text] [Related]
19. Resistance to CDK4/6 inhibition: Mechanisms and strategies to overcome a therapeutic problem in the treatment of hormone receptor-positive metastatic breast cancer.
Papadimitriou MC; Pazaiti A; Iliakopoulos K; Markouli M; Michalaki V; Papadimitriou CA
Biochim Biophys Acta Mol Cell Res; 2022 Dec; 1869(12):119346. PubMed ID: 36030016
[TBL] [Abstract] [Full Text] [Related]
20. Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation.
Torres-Guzmán R; Ganado MP; Mur C; Marugan C; Baquero C; Yang Y; Zeng Y; Bian H; Du J; de Dios A; Puig O; Lallena MJ
Oncotarget; 2022; 13():864-875. PubMed ID: 35813283
[TBL] [Abstract] [Full Text] [Related]
[Next]
